Stock Analysis of Enliven Therapeutics Inc. (ELVN) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ELVN
Close 23.04
Change -0.770 / 3.23 %
Volume 392489
Vol Change 3666.00 / 0.943 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Enliven Therapeutics Inc.
PE (TTM)

-11.95

Very Poor
Price / Book

3.41

Very Poor
Price / Sales

2162.17

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

1083.73 M

Enterprise Value

983919 K

ROA (TTM)

-26.89

Very Poor
ROE (TTM)

-28.51

Very Poor
Net Margin (TTM)

-18090.45

Very Poor
Revenue

%

0
Net Profit

4910.75 %

-71584.00 K
Debt to Equity

0.0014

Excellent
Altman Z Score

24.29

Excellent
Quick Ratio

0

Poor
Cash Ratio

9.78

Excellent


Highs/Lows of Enliven Therapeutics Inc.
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week23.43 1.66 % 1.54 % 25.022.92114-May-2417-May-24
Two Week22.65 1.72 % 3.42 % 25.15522.209-May-2406-May-24
One Month17.3 33.18 % 5.60 % 25.15515.9609-May-2419-Apr-24
Three Month16.79 37.22 % 5.95 % 26.010.900111-Apr-2415-Mar-24
Six Months10.4 121.54 % 17.48 % 26.09.8411-Apr-2412-Dec-23
One year20.0 15.20 % 27.52 % 26.09.8411-Apr-2412-Dec-23
Two year20.16 14.29 % 29.70 % 89.449.8414-Feb-2312-Dec-23


Technical View of Enliven Therapeutics Inc.
RSI

58.89

Neutral
MACD

1.56

Bullish
ADX

28.39

Bullish
Super Trend

19.82

Mild Bullish
Williams %R

-27.10

Strong Bearish
CCI

51.42

Neutral


EMA 5

23.57

Strong Bearish
EMA 15

22.49

Bullish
EMA 50

19.67

Bullish
EMA 100

17.96

Strong Bullish
SMA 100

17.03

Strong Bullish
SMA 200

15.36

Strong Bullish
SMA 5 / 20

23.84 / 21.10

Bullish
SMA 15 / 50

22.37 / 18.88

Strong Bullish
SMA 50 / 200

18.88 / 15.36

Strong Bullish




Charts of Enliven Therapeutics Inc.


Returns of Enliven Therapeutics Inc. with Peers
Period / StockELVNCRONPHVSSLN
1 Week-1.66%4.69%-5.17%8.44%
1 Mth33.18%19.83%-4.01%6.68%
3 Mth37.22%27.75%-24.35%3.74%
6mth121.54%47.96%26.01%152.75%
1 Year15.20%65.71%139.41%322.02%
2 Year14.29%-18.08%15.95%136.50%
5 Years--80.58%--
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Enliven Therapeutics Inc. with Peers
Ratio / StockELVNCRONPHVSSLN
PE-11.95-24.63-10.43-40.03
P/B3.411.294.1698.45
ROA-26.89-5.09-37.79-44.48
ROE-28.51-5.24-39.91-245.93
Debt To Equity0.00140.00090.00050.0105
Revenue0
% 		90514.00 K
1.51 % 		0
% 		28041.00 K
60.23 %
Net Income-71584.00 K
4910.75 % 		-108057.00 K
35.96 % 		-107324.07 K
40.60 % 		-42618.00 K
5.26 %


Technicals of Enliven Therapeutics Inc. with Peers
Technical / StockELVNCRONPHVSSLN-
ADX28.3933.9010.6813.04
CMF-0.0401-0.071-0.0359-0.162
MFI46.8654.9933.3969.94
RSI58.8959.0641.5757.58
MACD Abv SignalTrueTrueFalseTrue
Price Above 50 MATrueTrueFalseTrue-
Price Above 200 MATrueTrueFalseTrue-


About : Enliven Therapeutics Inc.

Address : 6200 Lookout Road, Boulder, CO, United States, 80301
Tel : 720 647 8519
URL : https://www.enliventherapeutics.com
Code : ELVN, ISIN : US29337E1029, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 12_Mar_2020
Employee Count : 46

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.


Note : All Data Generated at the End of Trading Hours (EOD Data)